Dataset Information


S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.

ABSTRACT: BACKGROUND:The efficacy of a combination of a calcium channel blocker (CCB) plus chlorthalidone (diuretic) versus a CCB plus an angiotensin receptor blocker (ARB) in patients not responding to CCB monotherapy has not been evaluated previously. We plan to compare the efficacy and safety of S-amlodipine (CCB) plus chlorthalidone versus S-amlodipine plus telmisartan (ARB) combinations among hypertension patients unresponsive to amlodipine monotherapy. METHODS/DESIGN:This study is a prospective, randomized, double-blind, multicenter, parallel, non-inferiority phase 4 study. Hypertension patients who have been treated with amlodipine (5 mg) or S-amlodipine (2.5 mg) monotherapy for ?2 weeks and whose mean diastolic blood pressure (DBP) is greater than 90 mmHg will be randomized to either S-amlodipine (2.5 mg) plus chlorthalidone (25 mg) or S-amlodipine (2.5 mg) plus telmisartan (40 mg) therapy. The primary efficacy endpoint is mean sitting DBP change after 12 weeks of treatment. The study objective is to prove the non-inferiority of the former combination (test drug) as compared to the latter one (control) with a non-inferiority margin of 3 mmHg in mean DBP change. The secondary endpoints are 6-week DBP change, 6- and 12-week sitting systolic BP (SBP) change, and the attainment of the target BP (SBP?

PROVIDER: S-EPMC6011241 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC3703394 | BioStudies
| S-EPMC3955615 | BioStudies
| S-EPMC7526577 | BioStudies
| S-EPMC3954024 | BioStudies
2010-01-01 | S-EPMC3172072 | BioStudies
| S-EPMC8082198 | BioStudies
| S-EPMC3682653 | BioStudies
| S-EPMC8109895 | BioStudies
| S-EPMC5446818 | BioStudies
| S-EPMC5125808 | BioStudies